20040 19626

07 APR 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2003 (17.04.2003)

PCT

(10) International Publication Number
WO 2003/031475 A3

(51) International Patent Classification[7]: C07K 16/28, 16/46, A61K 39/395, 47/48, C12N 15/13, 15/70, 1/21, G01N 33/577, A61P 17/06, 37/00, 19/02, 35/04

(21) International Application Number: PCT/GB2002/004619

(22) International Filing Date: 10 October 2002 (10.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0124317.9 10 October 2001 (10.10.2001) GB

(71) Applicant (*for all designated States except US*): **CELLTECH R & D LIMITED** [GB/GB]; 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **POPPLEWELL, Andrew, George** [GB/GB]; 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **TICKLE, Simon, Peter** [GB/GB]; 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **ZINKEWICH-PEOTTI, Karen** [GB/GB]; 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **MORRISON, Robert, Kendall** [GB/GB]; 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(74) Agents: **MERCER, Christopher, Paul** et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: BIOLOGICAL PRODUCTS

Radioimmunoassay Results



(57) Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.

WO 2003/031475 A3

162162

ACTION